Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SGLT2 Inhibition as a Therapeutic Strategy to Reverse Arterial Stiffening in Aging

NCT06506422 is registered in ClinicalTrials.gov with University of Missouri-Columbia as lead sponsor.

NCT NCT06506422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06506422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SGLT2 Inhibition as a Therapeutic Strategy to Reverse Arterial Stiffening in Aging
Lead sponsor
University of Missouri-Columbia
Phase
Phase 2/3
Overall status
Recruiting
Start date
August 18, 2024
Completion date
February 28, 2029
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aging, arterial stiffness